EphA5 Antibody (YT-12): sc-73947
- EphA5 Antibody (YT-12) is a mouse monoclonal IgG1 κ provided at 100 µg/ml
- raised against the extracellular domain of EphA5 of rat origin
- recommended for detection of EphA5 of mouse, rat and human origin by WB, IF, IHC(P) and FCM
- At present, we have not yet completed the identification of the preferred secondary detection reagent(s) for EphA5 Antibody (YT-12). This work is in progress.
EphA5 Antibody (YT-12) is a mouse monoclonal IgG1 antibody that detects EphA5 in mouse, rat, and human samples through applications such as western blotting (WB), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), and flow cytometry (FCM). EphA5, a member of the Eph receptor subfamily, plays a crucial role in mediating cell-cell interactions during developmental processes, particularly in the central nervous system. Anti-EphA5 antibody (YT-12) targets this receptor primarily on the cell surface, where EphA5 interacts with ephrin-A5 and ephrin-B2 to regulate cellular signaling pathways that influence neuronal development and synaptic plasticity. Proper functioning of EphA5 is vital for maintaining the balance of excitatory and inhibitory signals in the brain, which is essential for cognitive functions and overall neural network stability. Dysregulation of EphA5 signaling has been implicated in various neurological disorders, making EphA5 an important target for research in neurobiology and potential therapeutic interventions. EphA5 monoclonal antibody (YT-12) serves as an invaluable tool for researchers aiming to explore the intricate roles of Eph receptors in cellular communication and their implications in health and disease.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
EphA5 Antibody (YT-12) References:
- Downregulation of EphA5 by promoter methylation in human prostate cancer. | Li, S., et al. 2015. BMC Cancer. 15: 18. PMID: 25609195
- DNA Methylation of the EphA5 Promoter Is Associated with Rat Congenital Hypothyroidism. | Wu, Y., et al. 2015. J Mol Neurosci. 57: 203-10. PMID: 26109526
- EPHA5 mediates trastuzumab resistance in HER2-positive breast cancers through regulating cancer stem cell-like properties. | Li, Y., et al. 2019. FASEB J. 33: 4851-4865. PMID: 30620624
- Differential expression of EphA5 protein in gastric carcinoma and its clinical significance. | Zhang, W., et al. 2019. Oncol Lett. 17: 5147-5153. PMID: 31186729
- EPHA5 mutation predicts the durable clinical benefit of immune checkpoint inhibitors in patients with lung adenocarcinoma. | Huang, W., et al. 2021. Cancer Gene Ther. 28: 864-874. PMID: 32759987
- EphA5 Silencing Increases the Radiosensitivity of ESCC Cells Through ATM-Dependent Pathway. | Zhang, R., et al. 2020. Cancer Manag Res. 12: 9539-9549. PMID: 33061640
- EPHA5 mutations predict survival after immunotherapy in lung adenocarcinoma. | Chen, Z., et al. 2020. Aging (Albany NY). 13: 598-618. PMID: 33288738
- Expression of EPHA5 in lung adenocarcinoma is associated with lymph node metastasis and EGFR mutation. | Liu, C., et al. 2022. APMIS. 130: 338-345. PMID: 35332588
- EPHA5 mutation was associated with adverse outcome of atezolizumab treatment in late-stage non-small cell lung cancers. | Li, Z., et al. 2022. BMC Pulm Med. 22: 356. PMID: 36123678
- Association between EPHA5 methylation status in peripheral blood leukocytes and the risk and prognosis of gastric cancer. | Han, X., et al. 2022. PeerJ. 10: e13774. PMID: 36164608
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
EphA5 Antibody (YT-12) | sc-73947 | 100 µg/ml | $322.00 |